登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由华中科技大学同济医学院附属协和医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07429721,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
12. Men and women of childbearing potential must agree to use effective contraception from the time of signing the informed consent until 1 year after the use of the study drug;
入选标准第 26 条
13. Men and women of childbearing potential must agree not to donate sperm or eggs (oocytes) or other reproductive cells from the time of signing the informed consent until 1 year after the use of the study drug;
入选标准第 27 条
Received targeted therapy, epigenetic therapy, other investigational drugs, or treatment using invasive research medical devices within 5 half-lives;
排除标准第 2 条
Received immune/non-immune-directed systemic therapy within 1 week;
排除标准第 3 条
Received cytotoxic therapy within 2 weeks;
排除标准第 4 条
Received proteasome inhibitors within 2 weeks;
排除标准第 5 条
Received immunomodulatory therapy within 1 week.
排除标准第 6 条
Received radiotherapy within 4 weeks (if the radiotherapy covered ≤5% of bone marrow reserve, the subject is eligible regardless of the radiotherapy end date);
排除标准第 7 条
2. Received allogeneic hematopoietic stem cell transplantation within 6 months or autologous hematopoietic stem cell transplantation within 3 months before infusion;
排除标准第 8 条
4. Received any treatment using vesicular stomatitis virus G (VSVG) pseudotyped virus;
排除标准第 10 条
5. ECOG performance status 0-2, with an expected survival of ≥ 3 months;
入选标准第 8 条
Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week before screening), recombinant human erythropoietin allowed; for patients meeting the ≥ 6 g/dL hemoglobin requirement at screening, red blood cell transfusions are allowed to maintain hemoglobin ≥ 6 g/dL;
入选标准第 10 条
Absolute neutrophil count (ANC) ≥ 600/μL (no use of granulocyte colony-stimulating factor (G-CSF) within 1 week before screening or pegylated G-CSF within 2 weeks before screening);
入选标准第 11 条
Platelet count ≥ 50,000/μL;
入选标准第 12 条
7. Normal renal function: Creatinine clearance (CrCl) (Cockcroft-Gault formula) ≥45 mL/min;
入选标准第 14 条
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0× the upper limit of normal (ULN);
入选标准第 16 条
Total bilirubin (TBIL) and alkaline phosphatase (AKP or ALP) ≤2.0× ULN (except for congenital hyperbilirubinemia, e.g., Gilbert's syndrome, direct bilirubin ≤1.5× ULN);
入选标准第 17 条
4. Disease must be measurable at screening, meeting one or more of the following criteria:
入选标准第 4 条
3. Had malignancies other than MM before screening, except for: malignancies treated with curative intent, with no known active disease ≥2 years prior to enrollment; or adequately treated non-melanoma skin cancer with no evidence of disease currently;
排除标准第 9 条
6. Within 6 months before infusion, tested positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA levels above the normal range; tested positive for hepatitis C virus (HCV) antibody with peripheral blood HCV RNA levels above the normal range; tested positive for human immunodeficiency virus (HIV) antibody; or tested positive for syphilis;
排除标准第 12 条
11. Women of childbearing potential must have a negative pregnancy test at screening and before drug infusion and must not be breastfeeding.
入选标准第 25 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07429721,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
1. Age ≥ 18 years, any gender; 2. Diagnosed with multiple myeloma (MM) according to IMWG diagnostic criteria; 3. Have received at least 2 lines of anti-MM treatment, with at least one full treatment cycle per line, and experienced disease progression during the most recent anti-myeloma treatment or within 12 months after it, confirmed by available clinical evidence; or deemed by the investigator to be refractory to both immunomodulatory agents and proteasome inhibitors, with disease progression during the most recent anti-myeloma treatment or within 2 months after it (according to IMWG diagnostic criteria); 4. Disease must be measurable at screening, meeting one or more of the following criteria: Serum M protein level ≥ 0.5 g/dL; Or urine M protein level ≥ 200 mg/24h; Or involved serum free light chain ≥ 10 mg/dL with abnormal serum free light chain κ/λ ratio; 5. ECOG performance status 0-2, with an expected survival of ≥ 3 months; 6. Bone marrow function test results (from screening or within 2 months prior) meet the following requirements: Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week before screening), recombinant human erythropoietin allowed; for patients meeting the ≥ 6 g/dL hemoglobin requirement at screening, red blood cell transfusions are allowed to maintain hemoglobin ≥ 6 g/dL; Absolute neutrophil count (ANC) ≥ 600/μL (no use of granulocyte colony-stimulating factor (G-CSF) within 1 week before screening or pegylated G-CSF within 2 weeks before screening); Platelet count ≥ 50,000/μL; Lymphocyte count ≥ 500/μL; 7. Normal renal function: Creatinine clearance (CrCl) (Cockcroft-Gault formula) ≥45 mL/min; 8. Liver function must meet the following criteria: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0× the upper limit of normal (ULN); Total bilirubin (TBIL) and alkaline phosphatase (AKP or ALP) ≤2.0× ULN (except for congenital hyperbilirubinemia, e.g., Gilbert's syndrome, direct bilirubin ≤1.5× ULN); Albumin ≥3 g/dL; 9. Cardiac function must meet the following criteria: Left ventricular ejection fraction ≥50% (by echocardiography or MUGA scan); No clinically significant pericardial effusion; No clinically significant electrocardiogram abnormalities; 10. Pulmonary function must meet the following criteria: Blood oxygen saturation ≥90% without oxygen supplementation; 11. Women of childbearing potential must have a negative pregnancy test at screening and before drug infusion and must not be breastfeeding. 12. Men and women of childbearing potential must agree to use effective contraception from the time of signing the informed consent until 1 year after the use of the study drug; 13. Men and women of childbearing potential must agree not to donate sperm or eggs (oocytes) or other reproductive cells from the time of signing the informed consent until 1 year after the use of the study drug; 14. The subject or their legal guardian agrees to participate in this clinical trial and signs the informed consent form (ICF), indicating that they understand the purpose and procedures of this clinical trial and are willing to participate in the study.排除标准:Exclusion Criteria:
1.During screening, participants who have received other anticancer treatments (based mainly on investigator judgment): Received targeted therapy, epigenetic therapy, other investigational drugs, or treatment using invasive research medical devices within 5 half-lives; Received immune/non-immune-directed systemic therapy within 1 week; Received cytotoxic therapy within 2 weeks; Received proteasome inhibitors within 2 weeks; Received immunomodulatory therapy within 1 week. Received radiotherapy within 4 weeks (if the radiotherapy covered ≤5% of bone marrow reserve, the subject is eligible regardless of the radiotherapy end date); 2. Received allogeneic hematopoietic stem cell transplantation within 6 months or autologous hematopoietic stem cell transplantation within 3 months before infusion; 3. Had malignancies other than MM before screening, except for: malignancies treated with curative intent, with no known active disease ≥2 years prior to enrollment; or adequately treated non-melanoma skin cancer with no evidence of disease currently; 4. Received any treatment using vesicular stomatitis virus G (VSVG) pseudotyped virus; 5. Had severe, uncontrolled infection symptoms (bacterial, viral, fungal, etc.) during the screening period; 6. Within 6 months before infusion, tested positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA levels above the normal range; tested positive for hepatitis C virus (HCV) antibody with peripheral blood HCV RNA levels above the normal range; tested positive for human immunodeficiency virus (HIV) antibody; or tested positive for syphilis; 7. Had symptomatic heart failure or other serious cardiac diseases such as severe arrhythmias: New York Heart Association (NYHA) class III or IV congestive heart failure; Experienced myocardial infarction or underwent coronary artery bypass graft (CABG) or coronary stent implantation within 6 months prior to signing the ICF; Had clinically significant ventricular arrhythmias, or a history of unexplained syncope (excluding cases caused by vasovagal response or dehydration); Had a history of severe non-ischemic cardiomyopathy; 8. Other clinically significant diseases, including: Primary immunodeficiency; Stroke or seizure within 6 months prior to screening; Clear clinical evidence of dementia or altered mental status; Parkinson's disease or Parkinsonian movement disorders or history thereof; 9. Undergoing surgery within 2 weeks of administration or planned surgery within 2 weeks after administration, except for surgeries under local anesthesia; 10. Administration of live attenuated vaccines within 1 month before dosing; 11. Known severe allergic reaction to QI-019B or any of its formulation components; 12. Known severe allergic reaction to tocilizumab; 13. Unsuitable for establishing intravenous access; 14. Other conditions deemed by the investigator to be unsuitable for participation in this study.
引自 ClinicalTrials.gov, NCT07429721, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07429721,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。